3 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
Follow dactolisib: new trials by email Literature Review of dactolisib trials Research Report on dactolisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa BEZ235 - Malignant PEComa (Perivascular Epithelioid Cell Tumors) | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2012-09-01 | 2013-08-02 | |
| BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer BEZ235 - Metastatic Breast Cancer | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2012-03-01 | 2012-06-07 | |
| BEZ235 Trial in Patients With Advanced Endometrial Carcinoma BEZ235 - Endometrial Cancer | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2012-03-01 | 2012-06-21 |
Angiomyolipoma (1) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Perivascular Epithelioid Cell Neoplasms (1) · Tuberous Sclerosis (1) · Uterine Neoplasms (1)
Spain (2) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Poland (1) · Russia (1) · Singapore (1) · Turkey (Türkiye) (1) · United States (1)